CTOs on the Move

Timicoin

www.timicoin.io

 
The most reliable, completely - decentralized, health information exchange is waiting for you.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Miguel Esparza
Chief Technology Officer Profile

Similar Companies

Orexigen

Orexigen`s commitment to patients is reflected in all that we do: we are a company driven by the knowledge that our work is important and the desire to make a difference. Orexigen offers prospective employees exciting challenges` unique opportunities for career growth` and a fast-paced environment that emphasizes innovation and achievement.

Standard Homeopathic Co (Hylands)

Standard Homeopathic Co (Hylands) is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Carson, CA. To find more information about Standard Homeopathic Co (Hylands), please visit www.hylands.com

Central Georgia Health Network

CGHN has been a trusted partner for Central Georgia independent physicians for over 20 years, with proven success in favorable payouts, dividends and contracting. This commitment to physician independence is at the very heart of CGHN`s identity. CGHN`s ownership structure ensures independent physicians in Central Georgia maintain a strong, controlling governance voice. CGHN is a growing, clinically-integrated network representing nearly 1,000 independent physicians, healthcare professionals and hospital partners across Central Georgia. Our goal is to deliver the best patient care experiences, while enhancing care quality and lowering costs.

EasyRead Copywriting

EasyRead Copywriting is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.